Who are Florastamin[18F] Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): [Ga-68]PSMA, PET Scan with [18F] VAT, 18F-rhPSMA-7.3, Fluoro-L-thymidine-(18F), 68Ga-PSMA-11, F-18 FPCIT.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/florastamin-18f-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Florastamin[18F] Injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Florastamin[18F] Injection (Florastamin[18F] Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PET imaging agent / radiopharmaceutical. Area: Diagnostic Imaging / Infectious Disease.

phase 3 PET imaging agent / radiopharmaceutical Diagnostic Imaging / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Florastamin[18F] Injection (Florastamin[18F] Injection) — HTA Co., Ltd.. Florastamin[18F] is a fluorine-18 labeled radiopharmaceutical that targets bacterial infection and inflammation for positron emission tomography (PET) imaging.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Florastamin[18F] Injection TARGET	Florastamin[18F] Injection	HTA Co., Ltd.	phase 3	PET imaging agent / radiopharmaceutical
[Ga-68]PSMA	[Ga-68]PSMA	Norbert Avril, M.D.	marketed	PET imaging agent / radiopharmaceutical	PSMA (prostate-specific membrane antigen)
PET Scan with [18F] VAT	PET Scan with [18F] VAT	Stony Brook University	marketed	PET imaging agent / Radiopharmaceutical	Vascular adhesion molecules (VAM)
18F-rhPSMA-7.3	18F-rhPSMA-7.3	Hackensack Meridian Health	marketed	PET imaging agent / radiopharmaceutical	PSMA (prostate-specific membrane antigen)
Fluoro-L-thymidine-(18F)	Fluoro-L-thymidine-(18F)	Assistance Publique - Hôpitaux de Paris	phase 3	PET imaging agent / radiopharmaceutical	Thymidine kinase 1 (TK1)
68Ga-PSMA-11	68Ga-PSMA-11	Weill Medical College of Cornell University	phase 3	PET imaging agent / radiopharmaceutical	PSMA (prostate-specific membrane antigen)
F-18 FPCIT	F-18 FPCIT	Asan Medical Center	phase 3	PET imaging agent / Radiopharmaceutical	Dopamine transporter (DAT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PET imaging agent / radiopharmaceutical class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
HTA Co., Ltd. · 1 drug in this class
Hackensack Meridian Health · 1 drug in this class
Norbert Avril, M.D. · 1 drug in this class
Weill Medical College of Cornell University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Florastamin[18F] Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/florastamin-18f-injection. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab